This difference could be attributed to the downregulation of their potential targets (e.g., BIRC2 baculoviral IAP repeat containing 2 (cIAP1) and MCL1 apoptosis regulator (MCL1)), important in tumor cell survival following TKI treatment. The gene discussed is BIRC2; the disease is neoplasm.